Orphan-Drug Designation for AR-42 for Central-Nervous-System Tumors

Share this article:

Arno Therapeutics, Inc. announced that the FDA has granted its request for orphan drug designation for AR-42 for the treatment of meningioma and schwannoma of the central nervous system. Meningioma and schwannoma are benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity for those affected individuals.

AR-42 is an orally available, broad-spectrum deacetylation inhibitor of both histone and non-histone proteins that play an important role in the regulation of gene expression, cell growth, and survival.

For more information, call (862) 703-7170 or visit www.arnothera.com.
Share this article:
You must be a registered member of ONA to post a comment.

Next Article in Drugs in the Pipeline

Sign Up for Free e-newsletters

What is this?

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs